Active Substance: Amikacin sulfate.
Overview
Welcome to Dwaey, specifically on MIACIN 500 page.
This medicine contains an important and useful components, as it consists of
Amikacin sulfateis available in the market in concentration
Amikacin
Renal impairment; vertigo, tinnitus. Discontinue if signs of ototoxicity, neurotoxicity or hypersensitivity occurs; lactation. Safety has not been established for treatment period >14 days. Monitor renal function before and during treatment. Lactation: excretion in milk unknown/not recommended
Tuberculosis, Complicated and recurrent urinary tract infections, Severe Gram-negative infections, Non-tubercular mycobacterial infections, Bacterial septicemia, Infections of the respiratory tract, Bones and joints, Central nervous system and skin and soft tissue, Intra-abdominal infections, Burns, Postoperative infections, Meningitis, Peritonitis, Neonatal sepsis
Pregnancy, perforated ear drum, myasthenia gravis, hypersensitivity.
1-10% Neurotoxicity,Nephrotoxicity (if trough >10 mg/L),Ototoxicity <1% Hypotension,Headache,Drug fever,Rash,Nausea,Vomiting,Eosinophilia,Paresthesia,Tremor,Arthralgia,Weakness,Allergic reaction Potentially Fatal: Ototoxicity, nephrotoxicity, neuromuscular blockade.
4
Amikacin binds to 30S ribosomal subunits of susceptible bacteria, thus inhibiting its protein synthesis.
Amphotericin B may lead to increased nephrotoxicity and reduced clearance of amikacin when used together. Potentially Fatal: Increased ototoxic or nephrotoxic effects with other nephrotoxic or ototoxic drugs. Enhanced neuromuscular blockade with neuromuscular blocking drugs. Increased risk of ototoxicity with potent diuretics.
Information not available